“The multiple milestones achieved throughout the first quarter and in recent weeks are creating momentum to help advance our goal to deliver a better path for cancer patients,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We made meaningful progress across all areas of the business, which include important clinical milestones, expanding our global patent portfolio and strengthening the balance sheet. These achievements leave us well positioned for continued progress throughout the balance of the year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPTH:
- BPTH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
- Bio-Path files to sell 484K shares of common stock for holders
- Bio-Path announces closing of $1.2M registered direct offering
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules